866-997-4948(US-Canada Toll Free)

Diabetic Macular Edema Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Apr 2013

Category :

Diabetes

No. of Pages : 136 Pages


Global Markets Directs, \'Diabetic Macular Edema Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Macular Edema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Macular Edema. 

Diabetic Macular Edema Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Diabetic Macular Edema.
  • A review of the Diabetic Macular Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Diabetic Macular Edema pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Diabetic Macular Edema.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Diabetic Macular Edema pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Diabetic Macular Edema Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Diabetic Macular Edema 10
Diabetic Macular Edema Therapeutics under Development by Companies 12
Diabetic Macular Edema Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Diabetic Macular Edema Therapeutics Products under Development by Companies 20
Diabetic Macular Edema Therapeutics Products under Investigation by Universities/Institutes 22
Companies Involved in Diabetic Macular Edema Therapeutics Development 23
F. Hoffmann-La Roche Ltd. 23
Allergan, Inc. 24
pSivida Corp. 25
Eli Lilly and Company 26
GlaxoSmithKline plc 27
Quark Pharmaceuticals, Inc. 28
Santen Pharmaceutical Co., Ltd. 29
Lux Biosciences, Inc. 30
Novagali Pharma SA 31
Astellas Pharma Inc. 32
iCo Therapeutics Inc. 33
Mesoblast Ltd 34
NicOx SA 35
SANWA KAGAKU KENKYUSHO CO.,LTD. 36
Regeneron Pharmaceuticals, Inc. 37
ThromboGenics NV 38
Foamix Ltd. 39
Molecular Partners AG 40
Aciont Inc. 41
Charlesson LLC. 42
Icon Bioscience, Inc. 43
Eleven Biotherapeutics 44
Ampio Pharmaceuticals, Inc. 45
Diabetic Macular Edema Therapeutics Assessment 46
Assessment by Monotherapy Products 46
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 52
ranibizumab - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
darapladib - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
iCo-007 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
dexamethasone acetate - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ocriplasmin - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Eylea - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
dexamethasone dipropionate - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Drug For Diabetic Macular Edema - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
dexamethasone acetate - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
PF-655 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
fluocinolone acetonide - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
CLT-003 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
betamethasone - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
danazol - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
MP-0112 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
ruboxistaurin - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
sirolimus - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
minocycline - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
AKB-9778 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
KH-902 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
LX-213 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Mesenchymal Precursor Cells For Diabetic Macular Edema - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
NCX-422 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
ALG-1001 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Steroid For Diabetic Macular Edema - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Plasma Kallikrein Inhibitors Programme - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Plasma Kallikrein Inhibitors Programme - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Plasma Kallikrein Inhibitors Oral Programme - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
EBI-018 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Vascular Adhesion Protein-1 Inhibitor - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Diabetic Macular Edema Therapeutics Drug Profile Updates 101
Diabetic Macular Edema Therapeutics Discontinued Products 123
Diabetic Macular Edema Therapeutics - Dormant Products 124
Diabetic Macular Edema Product Development Milestones 126
Featured News & Press Releases 126
Oct 05, 2012: NICE Publishes Draft Guidance On Novartis\'s Ranibizumab For Diabetic Macular Edema After Rapid Review 126
Sep 19, 2012: Aerpio Therapeutics Initiates Phase Ib/IIa Trial Of AKB-9778 In Diabetic Macular Edema 127
Sep 05, 2012: NICE Accepts Alimera Sciences\'s Iluvien Subgroup Data For Review 127
Aug 10, 2012: FDA Approves Lucentis For Treatment Of Diabetic Macular Edema 128
Aug 08, 2012: NICE Turns Down Alimera\'s Iluvien For Treatment Of Diabetic Macular Edema 130
Aug 01, 2012: Ampio Announces Successful Pre-IND Meeting With Ophthalmology Division Of FDA On Optina For Treatment Of Diabetic Macular Edema 131
Aug 01, 2012: pSivida Reports Alimera\'s Intention To Resubmit Application To FDA For ILUVIEN In DME Using Data From Completed Trials 132
Jul 26, 2012: Alimera Sciences\'s ILUVIEN Receives Marketing Authorization In Germany For Treatment Of Chronic Diabetic Macular Edema 132
Jul 26, 2012: FDA Advisory Committee Recommends Approval Of Roche\'s Lucentis For Treatment Of Diabetic Macular Edema 133
Jul 24, 2012: FDA Reviews Lucentis Ahead Of Panel Vote 134

Appendix 135
Methodology 135
Coverage 135
Secondary Research 135
Primary Research 135
Expert Panel Validation 135
Contact Us 136
Disclaimer 13

List of Table


Number of Products Under Development for Diabetic Macular Edema, H1 2013 10
Products under Development for Diabetic Macular Edema Comparative Analysis, H1 2013 11
Number of Products under Development by Companies, H1 2013 13
Number of Products under Development by Companies, H1 2013 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2013 15
Comparative Analysis by Late Stage Development, H1 2013 16
Comparative Analysis by Mid Clinical Stage Development, H1 2013 17
Comparative Analysis by Early Clinical Stage Development, H1 2013 18
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 19
Products under Development by Companies, H1 2013 20
Products under Development by Companies, H1 2013 (Contd..1) 21
Products under Investigation by Universities/Institutes, H1 2013 22
F. Hoffmann-La Roche Ltd., H1 2013 23
Allergan, Inc., H1 2013 24
pSivida Corp., H1 2013 25
Eli Lilly and Company, H1 2013 26
GlaxoSmithKline plc, H1 2013 27
Quark Pharmaceuticals, Inc., H1 2013 28
Lux Biosciences, Inc., H1 2013 30
Astellas Pharma Inc., H1 2013 32
iCo Therapeutics Inc., H1 2013 33
Mesoblast Ltd, H1 2013 34
NicOx SA, H1 2013 35
Regeneron Pharmaceuticals, Inc., H1 2013 37
ThromboGenics NV, H1 2013 38
Foamix Ltd., H1 2013 39
Molecular Partners AG, H1 2013 40
Aciont Inc., H1 2013 41
Charlesson LLC., H1 2013 42
Icon Bioscience, Inc., H1 2013 43
Eleven Biotherapeutics, H1 2013 44
Ampio Pharmaceuticals, Inc., H1 2013 45
Assessment by Monotherapy Products, H1 2013 46
Assessment by Stage and Route of Administration, H1 2013 48
Assessment by Stage and Molecule Type, H1 2013 51
Diabetic Macular Edema Therapeutics Drug Profile Updates 101
Diabetic Macular Edema Therapeutics Discontinued Products 123
Diabetic Macular Edema Therapeutics Dormant Products 124
Diabetic Macular Edema Therapeutics Dormant Products (Contd..1) 125

List of Chart


Number of Products under Development for Diabetic Macular Edema, H1 2013 10
Products under Development for Diabetic Macular Edema Comparative Analysis, H1 2013 11
Products under Development by Companies, H1 2013 12
Products under Investigation by Universities/Institutes, H1 2013 15
Late Stage Products, H1 2013 16
Mid Clinical Stage Products, H1 2013 17
Early Clinical Stage Products, H1 2013 18
Discovery and Pre-Clinical Stage Products, H1 2013 19
Assessment by Monotherapy Products, H1 2013 46
Assessment by Route of Administration, H1 2013 47
Assessment by Stage and Route of Administration, H1 2013 48
Assessment by Molecule Type, H1 2013 49
Assessment by Stage and Molecule Type, H1 2013 50

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *